| Abstrakt: |
Several studies have investigated the role of HIF-1α in predicting the prognosis of patients with glioblastoma, yielding contradictory results. Therefore, we performed a meta-analysis to document the correlation between HIF-1α and glioblastoma in individuals diagnosed with glioblastoma. We searched the PubMed, Cochrane Library, EMBASE, and Web of Science by January 25, 2024. Hazard Ratio (HR) was used to evaluate the relationship between HIF-1α and survival outcome, and Odds Ratio (OR) was adopted for tumor features.There was incorporation of nine observational studies with 607 individuals. The total prevalence of HIF-1α (higher than cut-off values) among individuals with glioblastoma was 0.72 (95% confidence interval (CI) = 0.68–0.75, I2 = 95.1%). There is a strong association between increased levels of HIF-1α in tumour tissues and shorter Overall Survival (OS) (HR = 1.82, 95% CI = 1.41–2.34, I2 = 13.7%). Subgroup analysis also indicated a correlation between higher levels of HIF-1α and reduced OS, specifically in the Asian population (HR = 1.48, 95% CI = 1.13–1.83, I2 = 41.5%). In addition, there was a correlation between HIF-1α and age (older vs. younger, OR = 2.19, 95% CI = 1.25–3.86, P = 0.260). High levels of HIF-1α expression were associated with poorer survival outcomes and other clinicopathological characteristics of glioblastoma. Integrating HIF-1α into prognostic tools for glioblastoma aids in predicting survival, categorising risk, and advising patients on suitable treatment regimens. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink